A variety of human monoclonal antibodies against epidermal growth factor receptor isolated from a phage antibody library  by Kurosawa, Gene et al.
lable at ScienceDirect
Biochemical and Biophysical Research Communications 480 (2016) 94e100Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcA variety of human monoclonal antibodies against epidermal growth
factor receptor isolated from a phage antibody library
Gene Kurosawa a, Mariko Kondo b, Yoshikazu Kurosawa a, *
a Division of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan
b Perseus Proteomics Inc., Tokyo, Japana r t i c l e i n f o
Article history:
Received 24 September 2016
Accepted 2 October 2016
Available online 5 October 2016
Keywords:
Phage-display Ab library
Anti-EGFR Ab
Therapeutic Ab
Mutation
Ab repertoire* Corresponding author. Department of Innovation
cine, Center for Research Promotion and Support, F
Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1
E-mail address: kurosawa@fujita-hu.ac.jp (Y. Kuro
http://dx.doi.org/10.1016/j.bbrc.2016.10.002
0006-291X/© 2016 The Authors. Published by Elseviea b s t r a c t
When the technology for constructing human antibody (Ab) libraries using a phage-display system was
developed, many researchers in Ab-related ﬁelds anticipated that it would be widely applied to the
development of pharmaceutical drugs against various diseases, including cancers. However, successful
examples of such applications are very limited. Moreover, researchers who utilize phage-display tech-
nology now show divergent ways of thinking about phage Ab libraries. For example, there is debate
about what should be the source of VH and VL genes for the construction of libraries to cover the whole
repertoire of Abs present in the human body. In the immune system, the introduction of mutations into V
genes followed by selection based on binding activity, termed Ab maturation, is required for the pro-
duction of Abs exhibiting high afﬁnity to the antigen (Ag). Therefore, introduction of mutations and
selection are required for isolation of Abs with high afﬁnity after isolation of clones from phage Ab li-
braries. We constructed a large human Ab library termed AIMS, developed a screening method termed
ICOS, and succeeded in isolating many human monoclonal Abs (mAbs) that speciﬁcally and strongly bind
to various tumor-associated Ags. Eight anti-EGFR mAbs were included, which we characterized. These
mAbs showed various different activities against EGFR-expressing cancer cells. In this paper, we describe
these data and discuss the possibility and necessity that the mAbs isolated from the AIMS library might
be developed as therapeutic drugs against cancers without introduction of mutations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Since the development of a method to produce monoclonal
antibodies (mAbs), numerous scientists have tried to identify
appropriate target antigens (Ags) and isolate mAbs that could be
used for immunotherapy against various malignancies [1e3]. Ac-
cording to the standard procedure for the development of a ther-
apeutic Ab against cancers, the target molecule should be selected
at the ﬁrst step. Usually a tumor-associated antigen (TAA) is the
target. Once the target is chosen, mouse mAbs that bind to this
target are isolated by using hybridoma technology [4]. After ex-
amination of the anti-tumor activity of individual clones, the most
promising clone is selected and the Ab is converted to either a
mouse/human chimeric Ab [5] or a humanized Ab [6].Center for Advanced Medi-
ujita Health University, 1-98,
192, Japan.
sawa).
r Inc. This is an open access articlTwo methods have been developed for producing fully human
mAbs. One method uses transgenic mice that encode human
immunoglobulin (Ig) genes [7]. To date, panitumumab, an anti-
EGFR Ab, is the only successful example of a human anti-TAA Ab
approved as a therapeutic drug against cancer [8]. The second
technology to produce fully human Abs is the construction of a
human Ab library by using phage-display technology [9]. Although
more than twenty years have passed since this technology was
developed, the researchers who are currently using phage-display
technology have not reached a consensus about the following is-
sues. (1) What is the best source of VH and VL genes for the con-
struction of libraries. (2) In the naive repertoire of human Abs, are
there Abs that bind to proteins that are naturally present on the
normal cell surface? (3)When a phage Ab library is constructed, the
H chain library and the L chain library are separately constructed
and then randomly combined. Do Abs in such a combinatorial Ab
library reﬂect the original combination of H and L chains? (4) In the
immune system, introduction of mutations into V genes is required
for the production of Abs with high afﬁnity to the Ag. It should be
difﬁcult to directly isolate Abs with high afﬁnity to the target Age under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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In 1998, we constructed a human Ab library, termed AIMS, by
using the phage-display system [10]. We initially used a conven-
tional panning method in the screening of the library. However, the
quality of the majority of the clones isolated by this panning
method was very poor in terms of speciﬁcity, afﬁnity and even
variety. We subsequently developed a method termed ICOS for
comprehensive isolation of mAbs bound to molecules on the cell
surface [11]. By using this method, we succeeded in identifying 29
TAAs, and we isolated 488 human mAbs that speciﬁcally bind to
one of these 29 TAAs [12,13]. Eight anti-EGFR Abs were included
among these Abs. In this article, we show data regarding the
characterization of these clones, we describe the variety of clones
obtained and we discuss the possibility that the Abs isolated from
the AIMS library could be candidates for therapeutic drugs without
introduction of mutations.
2. Material and methods
2.1. Cells and Abs
The cancer-derived cell lines and mAbs used in this study are
described in our previous papers [12,13]. Single-chain Fv (ScFv) was
converted to IgG1 and was used in experiments aimed at exami-
nation of the activities of growth inhibition of cancer cells in vitro
and in vivo.
2.2. BIAcore analysis
The dissociation constant of Ag/Ab complexes was measured
using the BIAcore system. The extracellular part of the EGFR was
synthesized and chemically coupled to the support on a biosensor
chip. The single-chain Fv form of an anti-EGFR Ab linked to the PP
form that had been described in our paper [14] was puriﬁed and
applied to the system according to the manufacturer's protocol.
2.3. Inhibition of cancer cell growth in vitro
The number of living cells was counted using the Cell Prolifer-
ation Kit II (XTT) (Roche, Basel, Switzerland). The principle of this
assay system was described previously [15]. Cells were suspended
at a concentration of 1.0  104 cells/ml, and 100 ml portions were
inoculated in each well of 96-well plates. After mAbwas added, the
cells were incubated for 5 days at 37 C. After 5 days of incubation
the number of living cells was counted.
2.4. Inhibition of cancer cell growth in athymic mice
BALB/c athymic mice at 5 weeks of age were used in this
experiment. HT-29 cells (5  106 cells) were injected subcutane-
ously into the athymic mice. Ab therapy was begun the day after
tumor injection. Treatments consisted of twice weekly i.p. in-
jections of Ab (0.25 mg in 0.5 ml PBS/body) for three weeks. Tumor
size was measured.
2.5. Immunohistochemical (IHC) analysis after resection of tumors
from athymic mice
Tumor tissues were resected from treated mice. Tumor tissue
was ﬁxedwith 4% paraformaldehyde in PBS for 5 min, and was then
frozen at 80 C. Frozen specimens were cut into 3e5 mm thick
sections and stained with primary Ab using anti-human IgG at a
concentration of 1 mg/ml for 60 min, followed by the secondary Ab,
rabbit anti-human g chain (2 mg/ml for 60 min) and then the ﬁnal
Ab, HRP Polymer-conjugated anti-Rabbit IgG (DAKO).2.6. Flow cytometric (FCM) analysis after resection of tumors from
athymic mice
HT-29 cells were injected subcutaneously into athymic nude
mice (n ¼ 4). When the tumor volume reached over 200 mm3, the
tumor lump was surgically removed from each mouse. Half of each
mouse tumor was processed into single cell suspensions, which
were then stained for FCM. The other half was cultured. After two
passages the cultured cells were used for FCM.
3. Results
3.1. Isolation of eight kinds of human mAbs against the EGFR
For construction of the human Ab library termed AIMS, we used
the following organs as the source of human Ig genes: tonsils and
umbilical cord blood, each from approximately ten people, pe-
ripheral blood from several people, and bone marrow cells from
one person. The total number of B lymphocytes collected was
estimated to be around 1010. The total number of independent
clones in the constructed library was 1011. Development of a
screening method, termed ICOS, allowed us to comprehensively
isolate mAbs that bind to molecules on the cell surface [11]. Ac-
cording to our original strategy we randomly isolated a large
number of mAbs by using 49 kinds of tumor-derived cell lines as
Ags. All of the isolated clones were classiﬁed by sequencing, and
different clones were individually screened by immunostaining.
The clones that preferentially and strongly stained the malignant
cells were chosen. Subsequently, the Ags recognized by those
clones were identiﬁed by mass spectrometry (MS). In general,
determination of the target Ag of each Ab by using MS is laborious
and time consuming. Since we obtained several hundred clones
whose target Ags were unknown, we developed a new strategy for
determination of these Ags [16]. Once an Ag was identiﬁed byMS, a
polypeptide corresponding to the extracellular portion of the
membrane protein was prepared and used to identify if any of the
other isolated clones bound to this Ag. In this way, we succeeded in
identifying 29 kinds of TAAs and in isolating 488 mAbs that bind to
one of these TAAs in a relatively short period of time [12,13].
The EGFR was one of the 29 TAAs identiﬁed. Table 1 provides
details of screenings in which anti-EGFR clones were isolated.
Twenty-nine anti-EGFR mAbs were included in the 20 screenings
shown in Table 1, which were obtained from screening using 49
kinds of different cell lines of 11 kinds of cancer, and two clinical
samples. The 29 mAbs consisted of 8 different clones as follows:
clone 048-006 was isolated 13 times; 048-040, 6 times; 059e152, 4
times; 057-09 twice; and the other 4 clones were isolated only
once. Fig. 1 shows FCM analysis of ﬁve different cell lines with ﬁve
different anti-EGFR clones and Erbitux. In the cases of the PC-14
and HT-29 cell lines, the order of mean ﬂuorescence intensity
(MFI) for the ﬁve clones was perfectly matched to the order of the
isolation number for each clone, suggesting that clones with
stronger binding activity to the target Ag are more easily isolated in
our cloning method.
Based on the Ig gene source of the AIMS library, wemight expect
that B cells from tonsils and peripheral blood cells would mainly
consist of matured cells. On the other hand, B cells from umbilical
cord blood and bone marrow should be naive cells. The sequences
of the VH and VL genes of the eight anti-EGFR Abs were compared
with those of germline genes. As shown in Fig. 2, four of these
antibodies, 067e176, 054e101, 059e152, and 048-040, were
encoded by the same set of germline genes, VH4-39 and VL3-3 h,
without mutation. Among these Abs, differences were found only
in the CDR3 region of the H chain. The sequence of the H chain of
048-006 and that of 059e173 was the same as that of the germline
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respective Ags of more than twenty TAAs, and the sequences of
these Abs were also the same as the germline sequences in most
cases. These results indicated that the size of the naive repertoire
that is generated by the simple joining of VH-D-JH, and of VL-JL, in a
human body is enormous, and that the Ab repertoire formed in the
AIMS library well covers the in vivo repertoire.
3.2. Characterization of the anti-EGFR Abs
As described above, Fig. 1 shows FCM analysis of ﬁve cell lines
with six anti-EGFR mAbs including Erbitux. It is well known that
A431 cells express the EGFR at an extremely high level [17]. Judging
from the MFI values obtained, the other four cell lines tested also
expressed the EGFR at high levels. Differences in MFI values among
the clones reﬂected not only differences in Ab binding activity but
also differences in the epitope recognized by each Ab. In the pre-
vious section, we pointed out that the order of the MFI value in the
case of PC-114 and HT-29 cells was matched to the order of the
isolated number of clones. This order was not observed in the case
of the other cell lines, suggesting that the epitopes recognized by
these ﬁve clones are heterogeneous.
Before describing further characterization of these Abs, here, we
brieﬂy summarize the results reported in our previous paper [12].
The anti-tumor activity of mAbs 048-006 and 059e152 was
examined in cancer-bearing athymic mice. These mAbs completely
inhibited the growth of A431 cells similar to the effect of Erbitux.
While 048-006 completely inhibited the binding of EGF to the
EGFR, 059e152 only partially inhibited this binding. The inhibitory
ability of 048-006 appeared to be the same as that of Erbitux. Thus,
mechanisms of antitumor activity mediated by 048-006 and
059e152 are likely to be different from each other. Additionally,
048-006 showed the strongest EGFR binding activity among the
clones isolated. In the present paper, the raw data regarding the
binding of 048-006 with EGFR as measured using the BIA core in-
strument is shown in Supplementary Fig. 1. The dissociation con-
stant (Kd) of the Ag/Ab complex was 0.025 nM. This value reaches
the best level of binding reported for anti-EGFR Abs, even among
mAbs that were isolated by the common hybridoma technology
after immunization of mice with Ags.
3.3. Effects of anti-EGFR Abs on cell growth in vitro
We analyzed the effects of the anti-EGFR mAbs on the in vitro
growth of cancer cells, using six kinds of cell lines: A431, CCF-RC1,
ACHN, PC-14, EBC-1 and HT-29, all of which express the EGFR at
high levels. Five mAbs: 048-006, 059e152, 057e091, 048-040 and
059e173 were examined. Erbitux and Vectibix were also used for
comparison. None of the Abs, including Erbitux and Vectibix,
inhibited the growth of CCF-RC1, EBC-1 or HT-29 cells. In the case of
PC-14 cells, three mAbs, Erbitux, Vectibix and 048-006, exerted
inhibitory effects, but the degree of inhibitionwas rather small. The
results of experiments using A431 and ACHN cells are shown in
Fig. 3(A), (B), respectively. Since an IgG type of Ab was used in this
experiment, an Ab concentration of 101 mg/ml corresponds to
0.6 nM. The 048-006, Erbitux and Vectibix mAbs strongly inhibited
the growth of A431 cells, with the minimum Ab concentration
showing growth inhibition being between 0.06 and 0.6 nM. Since
the Kd of the Ag/Ab complex of mAb 048-006 was 0.025 nM as
described in the previous section, these results indicated that the
binding of this mAb to the cell surface effectively inhibits cell
growth. The inhibitory effect of mAb 059e152 was several times
weaker than that of the other three mAbs. Judging from the MFI
values shown in Fig. 1, the amount of the 059e152 mAb that was
bound to the surface of A431 appeared to be greater than that of
Fig. 2. Comparison of the amino acid sequence of anti-EGFR mAbs and germline genes. (A) Heavy chains, (B) Light chains.
048-006 059-152 048-040 ERBITUX
40.6 26.8 34.8 56.4
PC-14
34.5 33.2 33.7 58.1
CCF-RC1
87.6 64.3 69.5 90.7
HT-29
34.7 42.8 51.5 50.8
A431
34.4 33.0 38.1 47.8
HLF
057-091
25.2
37.6
57.0
42.1
26.6
059-173
17.9
29.2
33.7
31.4
22.8
Fig. 1. Flow cytometric analysis (FCM) of the binding of ﬁve of the anti-EGFR mAbs isolated in this study, and of Erbitux, to different cell lines. Mean ﬂuorescence intensity (MFI)
values are indicated.
G. Kurosawa et al. / Biochemical and Biophysical Research Communications 480 (2016) 94e100 97mAb 048-006. The inhibitory effect of 057e091 was weaker again
than that of mAb 059e152, although the MFI value of 057e091 was
similar to that of 059e152. Thus, these Abs may inhibit cell growth
via highly divergent mechanisms. As shown in Fig. 3(B), the mode
of the inhibitory effects of these Abs on the growth of ACHN cells
appeared to be different from that on the growth of A431 cells.
Thus, in the case of A431, inhibitory effects were initially observedat Ab concentrations between 0.06 and 0.6 nM, and a very sharp
curve of antibody concentration dependence of inhibition was
observed. In the case of ACHN cells, on the one hand, 40% inhibition
of cell growth was observed even at Ab concentrations that were
several tens of times lower than the concentrations at which in-
hibition was observed in A431 cells. On the other hand, the curve
showing the concentration dependence of inhibition was much
Fig. 3. Inhibition of cell growth by anti-EGFR mAbs. (A) A431, (B) ACHN cells.
G. Kurosawa et al. / Biochemical and Biophysical Research Communications 480 (2016) 94e10098more gentle than that for A431 cells. Thus, even if the cells express
EGFR on the cell surface at an extremely high level, anti-EGFRmAbs
do not necessarily inhibit the growth of the cells. Thus, the mech-
anism of EGFR involvement in cell growth is heterogeneous, and
themechanism bywhich anti-EGFRmAbs inhibit cell growth is also
heterogeneous. However, as long as inhibition was observed, the
048-006 and 059e152 mAbs showed strong inhibitory effects on
the growth of cancer cells at an extremely low concentration that
was comparable to the inhibition of Erbitux and Vectibix.3.4. Effects of anti-EGFR Abs on the growth of tumor cells in
athymic nude mice
As mentioned above, in a previous paper [12] we reported that
mAbs 048-006 and 059e152 showed a strong antitumor activity
against A431 cells in cancer-bearing athymic mice. The strength of
inhibition was similar to that of Erbitux. In the present study we
examined the antitumor activity in athymic mice of ﬁve mAbs:
048-006, 059e152, 057e091, 048-040, and 059e173, and ﬁve kinds
of cell lines: CCF-RC1, ACHN, PC-14, EBC-1 and HT-29. Here, we
show one example where clear but unexpected results were ob-
tained.While none of the ﬁve anti-EGFRmAbs inhibited the growth
of HT-29 cells in vitro, two of the mAbs, 048-006 and 057e091,strongly inhibited the growth of these cells when injected into
athymic mice as shown in Fig. 4. On the other hand, the other four
mAbs including Erbitux did not have any inhibitory effect. On day
22 the mass of cells including the tumor-growing portion was
excised and cut into slices, and one slice was immunohistochemi-
cally stained with an Ab that can detect human Abs. In the cases of
048-006 and 057e091, the tumor cells were clearly stained, indi-
cating the presence of human Abs. On the other hand, the mass of
cells from the mouse to which Erbitux was applied was not stained,
indicating the absence of human Abs. In this experimental system,
the presence of human Abs in the tumor-growing portion indicates
the localization of anti-EGFR mAbs injected into the athymic
mouse. In order to understand why 048-006 and Erbitux had
different effects on HT-29 cells grown in athymic mice, the
following experiment was performed. HT-29 cells were grown in
athymic mice without the addition of any mAb until the tumor
volume reached over 200 mm3. The tumor cells were then excised
and analyzed using FCM. As shown in Supplementary Fig. 2, the
expression of EGFR on the surface of of the tumor cells was clearly
detected by the 048-006 Ab.
6(A), the expression of EGFR on the surface of the tumor cells
was clearly detected by the 048-006 Ab. On the other hand, ERBI-
TUX did not detect any signal on the cell surface. However, after the
Fig. 4. Inhibition of the growth of HT-29 cells injected into athymic mice by anti-EGFR monoclonal antibodies (Upper left) growth curve; (Bottom and right) immunohistochemical
(IHC) analysis of the presence of human antibody in the excised tumor mass.
G. Kurosawa et al. / Biochemical and Biophysical Research Communications 480 (2016) 94e100 99cells were cultivated and passaged twice, both the 048-006 mAb
and ERBITUX detected molecules at the same level on the cell
surface as shown in Supplementary Fig. 2. Binding of the 048-006
monoclonal antibody with the EGFR, measured using the BIAcore
instrument.
These observations could be interpreted as follows. The form of
the EGFR molecule detected by the 048-006 mAb and by ERBITUX
may differ. HT-29 cells might express both forms of the EGFR under
normal growing conditions. However, in the athymicmice the EGFR
might be present predominantly in the form that is detectable by
the 048-006 mAb. These different forms of the EGFR would explain
why ERBITUX did not inhibit HT-29 cell growth in athymic mice,
but the 048-006 mAb did.4. Discussion
When therapeutic mAbs are being developed against cancer, the
target molecule must be determined at the ﬁrst step. As shown in
this paper, however, Abs against the same Ag showa huge variety in
terms of epitope recognition, binding activity and function. While
our data suggested that Erbitux and the 048-006 mAb are very
similar in terms of the above three points, it turned out that these
two mAbs had different effects on cell growth in athymic mice, as
typically shown in Fig. 4. Thus, even if only one molecule such as
the EGFR is overexpressed, this overexpressed EGFR exerts a large
variety of cellular functions. Furthermore, the effects modulated by
anti-EGR mAbs should also be very heterogeneous. Therefore, in
the beginning, at least several candidate mAbs should be prepared
that show functional differences.
In order to construct a human Ab library by using phage-display
technology, a large number of VH and VL genes are required. Since a
large sequence diversity can be generated into hypervariable re-
gions of VH and VL domains by utilizing mixed codons and PCR, wepreviously designed an artiﬁcial V gene set that mimics the human
V gene repertoire and made an Ab library using this gene set
[18e20]. However, the quality of the library turned out to be very
poor and the isolated mAbs were useless. Most of the artiﬁcially
diversiﬁed V genes did not supply a useful Ag-binding site.
In the human body Ab-producing cells are distributed in organs
of the human body as follows. Development of B lymphocytes
proceeds in the bone marrow. After maturation of the B lympho-
cytes, they are then distributed throughout the whole body, mainly
through a lymphatic vessel, but also partly through the blood
vessels. Most of the B lymphocytes stay in various lymphatic or-
gans. The largest organ is the spleen. Furthermore, many lymph
nodes are distributed throughout the whole body; the tonsil is one
such lymph node. Using more than 1010 B lymphocytes derived
fromvarious organs frommore than thirty people, a large Ab library
composed of 1011 independent clones was constructed in 1998. Our
screening method termed ICOS did not seem to be appropriate in
the case where the target Ag is pre-determined. The target Ag was
artiﬁcially overexpressed on the cell surface and screening was
performed according to the ICOS method. The results suggested
that the molecules that were artiﬁcially expressed on the cell sur-
face did not function as good Ags in the ICOS method by unknown
reason.
Each Ab is formed by H and L chains. When a phage Ab library is
constructed, an H chain library and an L chain library are separately
constructed and then randomly combined. The important point
regarding the formation of a large Ab repertoire is the following.
Although the contribution of the L chain to the formation of an Ag-
binding site is equally important as that of the H chain, the
contribution of the H chain to the generation of an extremely large
repertoire is huge because of the effects of random nucleotide
insertion by terminal transferase. Therefore, when an Ab library is
being constructed, the size of the H chain library and that of the L
G. Kurosawa et al. / Biochemical and Biophysical Research Communications 480 (2016) 94e100100chain should be carefully considered.
In the immune system, introduction of mutations into V genes
followed by selection on the basis of binding activity, which is
called the Ab maturation step, is required for production of Abs
with high afﬁnity to the Ag. However, the data presented in this
study indicated that, if the repertoire size of the Ab library is huge,
it can be expected that Abs with strong afﬁnity to the target Ag are
present in the library.
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